HUTCHMED (China) Limited (HCM) is drawing attention after a series of clinical and regulatory milestones strengthened its late-stage pipeline. Shares closed higher on above-average volume, signaling strong momentum for the company. Recent progress includes positive Phase III results for sovleplenib in autoimmune hemolytic anemia, the launch of a pivotal trial for surufatinib in pancreatic cancer, and priority review status for savolitinib in gastric cancer. Together, these developments highlight HUTCHMED's expanding role in oncology and immunology, positioning the stock as one to watch in 2026.
Stock performance
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com